In non–small cell lung cancer (NSCLC), response to immune checkpoint blockade (ICB) is
associated with programmed cell death ligand 1 expression that is induced by interferon-γ …

Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit
only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung …

The efficacy of immune checkpoint blockade (ICB) varies greatly among metastatic non-
small cell lung cancer (NSCLC) patients. Loss of heterozygosity at the HLA-I locus (HLA …

Despite the clinical success of immune checkpoint blockade (ICB), in certain cancer types,
most patients with cancer do not respond well. Furthermore, in patients for whom ICB is …

The antitumor action of immune checkpoint blockade (ICB) is primarily mediated by CD8+ T
cells. How sensitivity to ICB varies across CD8+ T cell subsets and clonotypes and the …

The biological determinants of sensitivity and resistance to immune checkpoint blockers are
not completely understood. To elucidate the role of intratumoral T-cells and their association …

Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local
immunosuppression independent of major ICI targets (eg, PD-1). Clinical experience with …

Resistance to checkpoint-blockade treatments is a challenge in the clinic. We found that
although treatment with combined anti-CTLA-4 and anti-PD-1 improved control of …

Immune checkpoint blockade (ICB) is efficacious in many diverse cancer types, but not all
patients respond. It is important to understand the mechanisms driving resistance to these …

Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are poorly
understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate …